Hyperparathyroidism in Metastases of Prostatic Carcinoma:
A Biochemical, Hormonal and Histomorphometric Study

Rico, H.; Uson, Aurelio C.; Hernández, E. R.; Prados, Pedro Abad; P, Páramo González; Cabranes, José A.

doi:10.1159/000463996

Cited by 26 publications

(11 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another mechanism that may be responsible for the decreased bone mass observed is secondary hyperpara thyroidism [24], which can develop as a result of bone hunger syndrome [25] or a postulated subclinical deficit in vitamin D [26], However, this is probably not the mechanism involved in prostate cancer because the skele tal region most affected by hyperparathyroidism in hu man beings is the skull [27] and cranial bone mass did not differ from healthy controls. We do not think that the antihormonal treatment given these patients was respon sible for reduced bone mass because of the short time of administration and the fact that hypogonadism produces its effects during skeletal development [28], not in adults [29], Further study is needed to clarify the cause of dimin ished bone mass in metastatic prostate cancer.…”

Section: Discussionmentioning

confidence: 99%

Total and Regional Bone Mass in Metastatic Cancer of the Prostate

Rico¹,

Ms²,

Revilla³

et al. 1996

Eur Urol

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Total and Regional Bone Mass in Metastatic Cancer of the Prostate

Rico¹,

Ms²,

Revilla³

et al. 1996

Eur Urol

Self Cite

View full text Add to dashboard Cite

“…There have been a number of reports of low serum calcium levels 77,78 and high PTH levels in patients with advanced prostate cancer. 79 Secondary hyperparathyroidism may occur frequently and may contribute to the generalised osteoclastic activity in patients with osteoblastic metastasis. 80 High PTH levels are associated with increased bone resorption and degradation of the bone matrix and may worsen any skeletal disease secondary to androgen deprivation.…”

Section: Calcium Homeostasis and Prostate Bone Metastasismentioning

confidence: 99%

The potential role of bisphosphonates in prostate cancer

Oades

Coxon

Colston

2002

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Skeletal morbidity secondary to metastases and osteoporosis is common in patients with advanced prostate cancer. Despite the typically sclerotic nature of prostate cancer metastases, osteoclast mediated osteolysis may play a significant role. This review addresses the newly recognised antitumour effects of bisphosphonates in addition to their role in inhibiting osteoclast mediated bone resorption. Both preclinical and clinical evidence of a role for bisphosphonates in the treatment and prevention of bone metastases secondary to prostate cancer is assessed.

show abstract

“…Osteoblast metastases may lead to calcium entrapment in bone and subsequent increase of parathyroid hormone (PTH) secretion as a response to lowering serum calcium levels. This metabolic picture, called ''Bone Hunger Syndrome,'' may also be responsible for a PTH mediated stimulation of osteoclast activity in sites distant from those involving the tumor, thus explaining erosive changes identified in bone remote from tumor deposits [3,5,6]. This metabolic derangement may contribute to morbidity (bone pain and bone fractures) and a worsening quality of life.…”

Section: Introductionmentioning

confidence: 99%